Pathophysiology of NASH in endocrine diseases

in Endocrine Connections
View More View Less
  • 1 K Gariani, Service of Endocrinology, Diabetes, Hypertension and Nutrition, Geneva University Hospital, Geneva, 1205, Switzerland
  • 2 F Jornayvaz, Service of Endocrinology, Diabetes, Hypertension and Nutrition, Hopitaux Universitaires de Genève, geneva, Switzerland

Correspondence: François Jornayvaz, Email: Francois.Jornayvaz@hcuge.ch

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the industrialized world. NAFLD encompasses a whole spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. The latter can lead to hepatocellular carcinoma. Furthermore, NASH is the most rapidly increasing indication for liver transplantation in western countries and therefore represents a global health issue. The pathophysiology of NASH is complex and includes multiple parallel hits. NASH is notably characterized by steatosis as well as evidence of hepatocyte injury and inflammation, with or without fibrosis. NASH is frequently associated with type 2 diabetes and conditions associated with insulin resistance. Moreover, NASH may also be found in many other endocrine diseases such as polycystic ovary syndrome, hypothyroidism, male hypogonadism, growth hormone deficiency or glucocorticoid excess, for example. In this review, we will discuss the pathophysiology of NASH associated with different endocrinopathies.

If the inline PDF is not rendering correctly, you can download the PDF file here.

 

     European Society of Endocrinology

     Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 426 426 229
PDF Downloads 954 954 591